Isis Pharmaceuticals, Inc. (ISIS) Posts Q2 Loss of 10c/Share

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) reported Q2 EPS of ($0.10), $0.02 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $57.1 million versus the consensus estimate of $45.6 million.

The company reported pro forma net operating income of $1.1 million and a pro forma net operating loss (NOL) of $21.5 million for the three and six months ended June 30, 2014, respectively, compared to an NOL of $5.3 million and $799,000 for the same periods in 2013.

For earnings history and earnings-related data on Isis Pharmaceuticals, Inc. (ISIS) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
• Onto Innovation gains on bullish RBC initiation citing advanced packaging growth